about
Immune response to Mycoplasma pneumoniae P1 and P116 in patients with atypical pneumonia analyzed by ELISAThe cancer stem cell: evidence for its origin as an injured autoreactive T cellExosomes released from Mycoplasma infected tumor cells activate inhibitory B cellsData-driven Decisions: The Importance of Clinical Trials in Arrhythmia Management.Protein and antigen heterogeneity among strains of Mycoplasma fermentansIdentification and characterization of serotype 4-specific antigens of Ureaplasma urealyticum by use of monoclonal antibodiesFulminant Mycoplasma pneumoniae pneumonia.NK cells interfere with the generation of resistance against mycoplasma respiratory infection following nasal-pulmonary immunization.Mycoplasma pneumoniae infection and neurological disease.The seroprevalence of Mycoplasma pneumoniae IgM and IgG antibodies in patients with ischemic strokeDiagnosis of Mycoplasma pneumoniae infection in autopsy and open-lung biopsy tissues by nested PCR.Sperm-mediated DNA transfer to cells of the uterus and embryo.Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to Mycoplasma pneumoniae in human serum.Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implicationsMycoplasma infections and different human carcinomas.Bronchiolitis obliterans due to Mycoplasma pneumoniae.Gulf War illnesses: complex medical, scientific and political paradox.Role of superoxide anion in host cell injury induced by mycoplasma pneumoniae infection. A study in normal and trisomy 21 cells.Mycoplasma pneumoniae infections in a rural setting in CanadaGrowth inhibition of Ureaplasma urealyticum by the proton pump inhibitor lansoprazole: direct attribution to inhibition by lansoprazole of urease activity and urea-induced ATP synthesis in U. urealyticumIn vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.Throat colonization of neonatal nursery staff by Ureaplasma urealyticum: An infection control or occupational health consideration?Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammationFever in a newborn.Mycoplasma pneumoniae and its role as a human pathogen.Mycoplasma-mediated uptake of the exogenous human BRCA1 gene by hatching blastocystsHost discrimination of Mycoplasma pneumoniae proteinaceous immunogensPhysical mapping of the Mycoplasma pneumoniae genomeIntranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumoniaAn adult case of Fisher syndrome subsequent to Mycoplasma pneumoniae infection.Changes in sexually transmitted disease.Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective.Genital mycoplasmas in placental infections.Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newbornsMycoplasma pneumoniae infection and environmental tobacco smoke inhibit lung glutathione adaptive responses and increase oxidative stressThe role of mycoplasmas in non-gonococcal urethritis: a reviewClinical features of mycoplasmal pneumonia in adults.Incidence of genital mycoplasmas in women at the time of diagnostic laparoscopy.Epidemiologic aspects of M. pneumoniae disease complications: a review.The principal protein antigens of isolates of Mycoplasma pneumoniae as measured by levels of immunoglobulin G in human serum are stable in strains collected over a 10-year period.
P2860
Q24799609-DF244154-4DF2-45CE-B432-6370376BF0BFQ25256839-0D24A242-247A-48C9-83B6-0C65E3610E74Q28482681-F1543291-B883-43BD-817B-08967A346059Q33179799-8F47ABD2-0429-495E-AC56-590B2B5A2170Q33370258-E1FEB350-DBC4-4DD9-A5C3-D1FDE6A8F67FQ33598383-8E2ECFC9-DCE7-4482-BE79-0EA38EC8A789Q33608196-3830CEB3-7005-4F69-ABE2-B79C8CCCE75FQ33612900-07B709D5-7E29-4920-B785-0FF9701436A4Q33624055-CC6FBF82-B37A-497A-9216-047CE86AD0E8Q33645328-132F1771-D65B-4866-8EE9-944E4338E07DQ33662147-11EFA9D0-2C82-4A05-A931-2AA1C9B4B3FAQ33926197-3030EC85-7F89-4DF9-9948-AB486ACDD49EQ33998608-A3E699A7-F626-4D38-93B4-FB9843D5AFFDQ34023899-7A952487-1C5E-4AD6-9DA8-DFA0090A96BBQ34112033-FB12184D-93A6-486F-A686-09E6A1F4EFFFQ34193615-FC4AE12D-3EE1-42B0-8EB8-86A0BB7D693FQ34472548-4AAD4AC9-05FA-4176-9D8E-91EB0DDDF240Q34606187-43046A0A-9A71-45B0-919A-1C02B9BFAF02Q34732373-F3BCEBA5-5151-4326-924A-A0510372CC32Q35119160-15EA504E-E9A3-4D19-AB7A-B26F1CFB2BFCQ35564364-622E90C4-1503-468A-986F-AFA1D513AD52Q35649972-D75C0A0E-A9A7-419D-B0DD-7C4906D08189Q35689129-F48588F4-CD0A-449F-A3F7-F56947658768Q35775023-9FD573DD-4657-48EE-891D-E4DF42624C14Q35920629-C44A5F7F-DD93-447E-A9F5-6A9DFB8A131BQ36270149-0DF1D282-F915-454F-9F41-306021021BABQ36347536-82B147CB-EE3A-4E5C-82C3-42BC2B760018Q36355483-E5D12DFB-9BBD-4FA6-8341-3F25C3C57CDAQ36421600-0B2BAAE7-A16E-46FA-B9D5-D1A4C76A118AQ36536291-0323E640-A8A3-42E8-AFC0-AE3EA074DE1CQ36576008-521C0949-3661-4137-9374-6B394099B01BQ36582458-3743A9EF-9330-4041-A3ED-4D5523CC721DQ36624514-F6A881C9-1B1B-4B3C-B13F-F11F653DF85FQ36639538-E53DC384-A0D5-4B6B-BAD7-01C3326F2E31Q36898472-4D275C68-79EA-413D-8529-32B37BF38114Q36989777-6251E17E-330E-4BC7-BBAE-49919210DCE9Q36989782-1EC2E954-AD7D-49D6-8FBF-D6734E9C67FFQ36989816-061716F4-EC0D-44F5-BF29-37B5791E655AQ36989844-1A1A202B-EFCF-48A8-B385-A862DC448862Q37021748-99435BF3-0A24-495E-8D88-5BE0E3EFAA1D
P2860
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Mycoplasmas as agents of human disease.
@en
type
label
Mycoplasmas as agents of human disease.
@en
prefLabel
Mycoplasmas as agents of human disease.
@en
P1476
Mycoplasmas as agents of human disease.
@en
P2093
P356
10.1056/NEJM198101083040204
P407
P577
1981-01-01T00:00:00Z